Abstract
Background and Aims:
Despite improvements to the diagnosis and treatment of early-stage tumours, prostate cancer remains the fifth most common cause of cancer death among men. This has been primarily attributed to metastatic disease progression. Matrix Metalloproteinase 14 (MMP14) is thought to promote cancer metastasis. However, MMP14’s role in prostate cancer progression is still unclear. Thus, we systematically evaluated existing literature on the relationship between MMP14 and prostate cancer.
Methods:
A search of PubMed, Embase, and Web of Science was conducted following PRISMA-ScR guidelines. Multiple screening stages were conducted with eligibility criteria inclusive of clinical, animal, and cell-based experimental studies relevant to MMP14 and prostate cancer. Data on populations, methodology, comparators, and outcomes were extracted and synthesised.
Results:
Of the 2408 studies screened, 63 met inclusion criteria. MMP14 expression was found to have a direct influence on the ability of prostate cancer cells to cleave extracellular matrix components such as collagen, fibronectin, and laminin, and activate molecules that regulate metastasis. Through these mechanisms, MMP14 can directly regulate the invasiveness of prostate cancer cells. Animal studies highlight MMP14’s potential in-vivo, showing that MMP14 directly stimulates tumour growth and metastasis. Interestingly, clinical studies found conflicting results, with MMP14 expression in cancer tissue being either significantly associated or not associated with prostate cancer formation and progression.
Conclusions and Significance/Impact:
While In-vitro and In-vivo studies highlight the key role of MMP14 in prostate cancer development, little evidence is presented by clinical studies to support this relationship. These conflicting results may be driven by low cohort size, errors in study design, and/or difficulties with translation of results from non-physiological in-vitro studies. The use of physiologically relevant 3D cultures and larger cohort studies could therefore bridge these gaps and highlight the role of MMP14 in prostate cancer progression and as a biomarker for prognosis and treatment.
Despite improvements to the diagnosis and treatment of early-stage tumours, prostate cancer remains the fifth most common cause of cancer death among men. This has been primarily attributed to metastatic disease progression. Matrix Metalloproteinase 14 (MMP14) is thought to promote cancer metastasis. However, MMP14’s role in prostate cancer progression is still unclear. Thus, we systematically evaluated existing literature on the relationship between MMP14 and prostate cancer.
Methods:
A search of PubMed, Embase, and Web of Science was conducted following PRISMA-ScR guidelines. Multiple screening stages were conducted with eligibility criteria inclusive of clinical, animal, and cell-based experimental studies relevant to MMP14 and prostate cancer. Data on populations, methodology, comparators, and outcomes were extracted and synthesised.
Results:
Of the 2408 studies screened, 63 met inclusion criteria. MMP14 expression was found to have a direct influence on the ability of prostate cancer cells to cleave extracellular matrix components such as collagen, fibronectin, and laminin, and activate molecules that regulate metastasis. Through these mechanisms, MMP14 can directly regulate the invasiveness of prostate cancer cells. Animal studies highlight MMP14’s potential in-vivo, showing that MMP14 directly stimulates tumour growth and metastasis. Interestingly, clinical studies found conflicting results, with MMP14 expression in cancer tissue being either significantly associated or not associated with prostate cancer formation and progression.
Conclusions and Significance/Impact:
While In-vitro and In-vivo studies highlight the key role of MMP14 in prostate cancer development, little evidence is presented by clinical studies to support this relationship. These conflicting results may be driven by low cohort size, errors in study design, and/or difficulties with translation of results from non-physiological in-vitro studies. The use of physiologically relevant 3D cultures and larger cohort studies could therefore bridge these gaps and highlight the role of MMP14 in prostate cancer progression and as a biomarker for prognosis and treatment.
| Original language | English |
|---|---|
| Pages | 127-127 |
| Number of pages | 1 |
| Publication status | Published - 7 Nov 2025 |
| Event | 64th ASMR National Scientific Conference: Advancing Human Health through Discovery and Innovation - The Stamford Plaza Hotel, Brisbane CBD, Brisbane, Australia Duration: 6 Nov 2025 → 7 Nov 2025 https://asmr.org.au/nsc/ |
Conference
| Conference | 64th ASMR National Scientific Conference: Advancing Human Health through Discovery and Innovation |
|---|---|
| Country/Territory | Australia |
| City | Brisbane |
| Period | 6/11/25 → 7/11/25 |
| Other | The theme is “Advancing Human Health through DIscovery and Innovation” and abstract topics can include but are not limited to: Foundational & Translational Research Innovation, Technology & Discovery Health Systems, Mental Health & Society Clinical & Applied Research Research Culture, Training & Careers Industry, Commercialisation & Partnerships Global & Planetary Health Science Communication & Advocacy Our stellar lineup of invited speakers come from virology and infectious diseases, maternal and fetal health, cardiac organoid technology and regenerative medicine, and immunology. There will also be skills development workshops addressing the application of AI in research and how to optimise your written and communication skills so you can better share your research. |
| Internet address |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'The Role of MMP-14 in the Development and Progression of Prostate Cancer: A Scoping Review'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver